BIM
CDTX

BlackRock Investment Management’s Cidara Therapeutics CDTX Stock Holding History

BlackRock Investment Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$466K Buy
2,239
+85
+4% +$17.7K ﹤0.01% 3065
2016
Q3 		$493K Sell
2,154
-5
-0.2% -$1.16K ﹤0.01% 3056
2016
Q2 		$445K Buy
2,159
+1,295
+150% +$313K ﹤0.01% 3117
2016
Q1 		$219K Buy
864
+17
+2% +$3.92K ﹤0.01% 3141
2015
Q4 		$291K Sell
847
-147
-15% -$44.1K ﹤0.01% 3168
2015
Q3 		$253K Sell
994
-15
-1% -$4.29K ﹤0.01% 3201
2015
Q2 		$283K Buy
+1,009
New +$310K ﹤0.01% 3235

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Investment Management's CDTX Position: Q4 2016 in Review

BlackRock Investment Management increased its Cidara Therapeutics (CDTX) stake by 3.9% in Q4 2016, buying an estimated $17.7K and bringing the position to 2,239 shares worth $466K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

BlackRock Investment Management first reported a position in CDTX in Q2 2015 and has held it in 7 quarters since. The position peaked at $493K in Q3 2016. 58 funds tracked by Wall St. Rank hold CDTX as of Q4 2016.

  • BlackRock Investment Management held 2,239 shares of Cidara Therapeutics worth $466K as of Q4 2016.
  • BlackRock Investment Management bought 85 Cidara Therapeutics shares in Q4 2016, an estimated $17.7K.
  • Cidara Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3065 holding.
  • BlackRock Investment Management first reported a position in Cidara Therapeutics in Q2 2015 and has held it in 7 quarters since.
  • BlackRock Investment Management's Cidara Therapeutics position peaked at $493K in Q3 2016.
  • 58 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.